TrialJournal for immunotherapy of cancer2023

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.

Giuseppe Lo Russo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.